drugset / Trial / NCT00238485

An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder

NCT00238485 ↗

Phase 3 Completed 251 enrolled Novartis
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

This extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/d over 52 weeks in patients who completed the 6-week double-blind study CLIC477D2302.

Timeline

Start
2005-01
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Licarbazepine Small molecule 750 mg —
Subject Licarbazepine Small molecule 2000 mg —

Indications